– USA, CA – Vir Biotechnology, Inc. (Nasdaq: VIR) announced the nominations of Dr. Norbert Bischofberger (Ph.D.) and Dr. Ramy Farid (Ph.D.) for their elections to its Board as Independent Directors at its upcoming AGM on May 29, 2024, to bring extensive mid-to-late-stage clinical development and computational/data sciences expertise, respectively.
The Company also announced that Dr. Phillip Sharp and Robert Perez will not stand for reelection at the Annual Meeting.
About Dr. Norbert Bischofberger
Norbert Bischofberger, Ph.D., brings close to 40 years of experience as a biotech executive and in research and development leadership roles to the industry. He is currently President and CEO, and a member of the Board of Directors, of Kronos Bio, Inc., a clinical-stage company dedicated to the discovery and development of therapeutics that target the deregulated transcription that causes cancer and other serious diseases. Before joining Kronos, he was EVP of research and Development, and CSO at Gilead Sciences, Inc., which he joined in 1990 as Director of Chemistry after having worked as a Senior Scientist in Genentech, Inc.’s DNA Synthesis Group from 1986 until 1990. During his 28-year tenure at Gilead, Dr. Bischofberger presided over the development and approval of more than 25 medicines for a range of serious conditions which led to the transformation of the treatment of diseases such as HIV and viral hepatitis, including HBV and HCV. Dr. Bischofberger was part of the core management team that grew Gilead from less than 50 employees with no revenue to 10,000 employees with $25B in revenue. He received a Ph.D. in organic chemistry from Zurich’s Eidgenössische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts. Dr. Bischofberger received an honorary doctorate in Natural Sciences (2016) from The University of Innsbruck and an honorary doctorate in Letters in Medicine (2017) from Baylor College of Medicine. He was elected a Fellow of The American Association for Advancement of Science (2018). In addition to Kronos Bio, Dr. Bischofberger serves on the Board of Directors of Morphic Therapeutic Inc., a U.S. publicly traded biopharmaceutical company, the Supervisory Board of Bayer AG, a multinational public company with core competencies in the life science fields of health care and agriculture, and the Biopharma Advisory Board of Ginkgo Bioworks.
About Dr. Ramy Farid
Ramy Farid, Ph.D., is President, CEO, and a member of the Board of Directors at Schrödinger, Inc., which has pioneered a physics-based computational platform that enables the discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost compared to traditional methods. He joined Schrödinger in 2002 and helped advance the company’s computational platform and drug discovery portfolio while assuming positions of increasing responsibility before becoming CEO in 2017. Dr. Farid has played a key role in implementing major strategic initiatives, including more than 40 research collaborations and joint ventures, and led the company through its initial public offering in 2020. Dr. Farid currently serves on the board of directors of Ajax Therapeutics, Inc. and Structure Therapeutics Inc., a U.S. publicly traded biopharmaceutical company. Previously, he served on the board of directors of Nimbus Therapeutics, a biotechnology company he helped found in 2009. He also served on the board of directors of Morphic Therapeutic, Inc. Dr. Farid currently serves on Morphic Therapeutic’s scientific advisory board. Dr. Farid began his career in academia and was an assistant professor in the chemistry department at Rutgers University. He was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his doctorate in chemistry from Caltech. He is an author of over 100 peer-reviewed publications.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/M P, V, and HPV. Vir routinely posts information that may be important to investors on its website.
SOURCE: https://www.vir.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.